The trend: Healthcare professionals are worried that social media influence promotes unhealthy fad diets, per a new Sermo survey. Our take: Healthcare professionals risk losing credibility with patients, who are turning to more relatable (albeit maybe more unreliable) social media influencers. Doctors and nurses will need to enroll in CME nutrition courses and lean into their medical expertise when patients are in the office to offer guidance on nutrition, without seeming heavyhanded.

The news: Pharma companies can earn a speedier path to approvals for new drugs if they agree to lower US prices to global levels. The takeaway: Pharma companies are on board with faster drug approvals and higher global prices, but they still make the bulk of their profits on US sales. By adopting good faith balanced stances—advocating for fairer pricing, but highlighting innovation—pharma can notch wins with the administration and consumers.

The data: About 2 in 3 people have at some point decided not to fill or refill a prescription medication, according to the M3 MI MARS Consumer Health Study of over 20,000 US adults. The final word: Pharma companies should create informational resources on the reasons side effects occur, while being transparent at the onset about what patients should expect. Drugmakers can also tap into digital channels such as online patient communities and social media platforms like Reddit, where patients regularly discuss their experiences with treatments. This could help brands gather insights that inform future drug development or the creation of new patient support programs.

The news: President Trump is threatening 200% tariffs on pharma products, but the 1+ year lag in enforcement gives drugmakers time to increase US manufacturing. Our take: While 200% is an exorbitant tariff rate, the year-long reprieve is a win for drugmakers. It gives them time to move product and double down on US manufacturing commitments, and also opens a big window for change with the capricious Trump administration.

The news: Mattel introduced the first Barbie doll with type 1 diabetes, sporting a glucose monitor and insulin pump. Our take: Pharma insulin makers like Sanofi, Eli Lilly, and Novo Nordisk, and device companies like Dexcom, Abbott, and Medtronic can leverage the type 1 Barbie news to drive more awareness and visibility and dispel stigma and the embarrassment kids with diabetes may feel.

The news: Hims & Hers will soon expand its business to Canada, where it plans to sell generic semaglutide. The bottom line: Novo just gave a massive gift to healthcare companies that are in the weight loss drug market but can no longer sell compounded GLP-1s now that the brand-name versions are available again. We’ll likely see more players in this space that primarily operate in the US expanding north of the border, while others could take advantage of President Trump’s executive order that calls for the FDA to authorize more states to import lower-cost drugs from Canada.

The news: Samsung’s just released Galaxy Watch 8 series comes equipped with new health and wellness features for sleep, stress, and activity. Our take: Samsung’s new features (e.g., antioxidant measuring, vascular load) are too niche to move the needle in consumer adoption. Health wearable players should lean into product capabilities that easily integrate with smartphone apps and that aren’t overly complex or clinical, such as chatbots delivering personalized recommendations based on user activity, exercise, and nutrition data.

The news: Several leading medical associations representing hundreds of thousands of US clinicians, as well as scientists, researchers, and public health workers, have sued HHS Secretary Robert F. Kennedy Jr. and other top health officials over the government’s recent decision to make COVID-19 vaccines more restrictive. The big takeaway: Kennedy is running out of allies in the medical and pharma communities. If nothing else, the lawsuit could force Kennedy and his team to adhere to the legal framework in place for making sudden changes that disrupt the public’s access to vaccines.

The news: Healthline Media settled with the California Attorney General’s office over allegations that Healthline.com failed to opt consumers out of having their personal information shared for targeted advertising. Our take: State health data privacy laws are new, meaning we will likely see increased scrutiny and more enforcement action against companies that previously went unchecked. Healthline and other health content companies must verify that their opt-out tools work as intended while being transparent with advertisers about the consumer data they can and cannot share with them.

The news: The newly passed Trump federal budget slashes healthcare spending by more than $1 trillion over the next 10 years. The takeaway: The cascading effect of federal spending cuts to Medicaid and ACA is poised to reshape US healthcare with more uninsured patients, lower payments and higher costs for physicians and healthcare systems, rural hospital closings, and increased costs for insurers. We expect advanced cost-cutting measures and lobbying for concessions as the industry braces for the initial effects next year.

The news: Dr. Kim Boyd, previously the chief medical officer of telehealth weight loss startup Calibrate, joins WeightWatchers as CMO as the company plans to launch perimenopause, menopause and post-menopause treatments and services for women ages 40-60 later this year. Our take: WeightWatchers will compete with several D2C telehealth for the underserved pre- and post-menopausal consumer market. However, we think its brand recognition among women ages 40-60, its long-standing weight loss support expertise and new Novo deal could catapult it ahead.

The trend: Pharma field teams saw 2.5 times more new patient starts if they used marketing content during healthcare provider visits, according to the Veeva Pulse Field Trends Report for Q1. The takeaway: Pharma marketing teams should focus on how the content they’re creating can boost field teams’ engagement with healthcare providers and advise reps on how and when to use materials.

The news: Spain is investigating Novo Nordisk over a controversial obesity awareness ad campaign tied to its weight loss drugs. Our take: GLP-1 weight loss drugs are in demand, but drugmakers can’t afford any trust gaps with health systems and physicians in the competitive race for customers.

The trend: Few consumers use AI tools for the health and wellness activities they participate in, according to a recent survey from Menlo Ventures and Morning Consult of 5,031 U.S. adults in April 2025. The big takeaway: Consumers are right on the cusp of using AI as a health information tool. AI tools are getting smarter, but can still be unreliable—one faulty response to a query about a person’s symptoms or health condition can turn a user off for good. AI platforms must train their models on credible medical sources and collaborate with clinicians to review outputs for accuracy.

The news: The Trump administration recently met with leading retailers, including Amazon and Walmart, to explore ways in which more US consumers can get their prescription medications directly from pharma manufacturers, according to a Bloomberg report. Our take: It’s unrealistic to expect pharma’s middlemen to be cut out anytime soon, as they are so deeply rooted in the US healthcare infrastructure.

The news: A Microsoft AI pilot study showed a fourfold improvement in diagnostics compared with a panel of real doctors, but researchers acknowledged the continued need for human expertise. The takeaway: It’s evident AI is not a replacement for doctors, but it is a tool they should start adopting. There’s a window of opportunity for doctors and healthcare systems to grab a first-mover advantage by presenting AI as a co-pilot and a value-add that leads to more accurate diagnoses and more time spent with patients.

The news: Pharma advertisers spent more than $10 billion on prescription drug ads last year, with the top 10 drug brands accounting for $3.3 billion last year, per Fierce Pharma’s report based on MediaRadar data. Our take: As pharma marketers shift drug ad budgets from TV to more digital channels, they’ll have to shift thinking from spendy brand awareness to more nuanced messaging. Social media edutainment, paid AI search ads, and partnering with doctor and patient influencers can reach more relevant consumers and deliver higher ROI.

The news: Here’s a look back at the most popular stories from January through June 2025. The final word: Gen Z’s healthcare attitudes, social health influencers, marketing strategies, and how patients use AI drew the most attention from our audience.

The news: Consumers who are more familiar with AI are also more likely to mistrust an AI-assisted diagnosis from their doctor, per a recently published Journal of Medical Internet Research survey. Our take: Physicians and healthcare marketers can’t assume people who are familiar with AI will be more comfortable with AI uses in healthcare. Marketers need to talk about AI as a tool with many positive effects like freeing doctors for longer personal interactions and resulting in fewer mistakes.

The trend: Most healthcare and pharma marketers plan to increase their CTV/over-the-top (OTT) spending in the next year, according to Nielsen’s Global Annual Marketing Survey. Our take: CTV’s gain of healthcare and pharma ad dollars isn’t necessarily linear TV’s loss. Campaign strategies for linear should focus on brand awareness, while CTV allows drug ads to be highly targeted.